Joby Aviation closes $591 million stock offering with full underwriter option
Director William D. Waddill of Protagonist Therapeutics (NASDAQ:PTGX) sold 4,000 shares of common stock on September 22, 2025, at a price of $64.25, for a total transaction value of $257,000. The transaction comes as the stock trades near its 52-week high of $66.70, having delivered an impressive 71% return year-to-date. According to InvestingPro data, the company’s market capitalization stands at $4.1 billion.
Following the transaction, Waddill directly owns 5,130 shares of Protagonist Therapeutics. The company maintains strong financial health with a current ratio of 16.97 and more cash than debt on its balance sheet. InvestingPro analysis indicates the stock is currently trading at premium valuations with a P/E ratio of 81.
The sale was executed under a Rule 10b5-1 trading plan adopted on November 10, 2023. The sale was reported in a Form 4 filing with the Securities and Exchange Commission. For deeper insights into insider trading patterns and 18 additional key investment tips for PTGX, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Protagonist Therapeutics has been the focus of several analyst updates. Barclays initiated coverage on the company with an Overweight rating and set a price target of $72.00. This decision was influenced by Protagonist’s peptide technology platform, which addresses various disorders. JMP Securities raised its price target for the company to $69.00, maintaining a Market Outperform rating. The firm expressed high confidence in the upcoming new drug application for rusfertide in polycythemia vera, expecting a 90% probability of approval next year. H.C. Wainwright reiterated its Buy rating with an $80.00 price target, emphasizing Protagonist’s strategic approach and successful partnerships with Takeda and Janssen. These developments highlight the company’s ongoing efforts and potential growth in the biotech sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.